| Study |
pts |
Treatment |
PFS |
OS |
| Williamson SK et al. [33] |
41 |
Sorafenib 400mg/mq 28 days |
4m |
9m |
| Elser C JCO et al. [20] |
26 |
Sorafenib 400 mg/mq d1-2 |
NR |
4,2m |
| Vokes EE et al. [25] |
51 |
Bevacizumab + erlotinib |
3.8m |
6.8m |
| Feinstein T et al. [34] |
25 |
Pem+ Beva |
NR |
RR =36%
DCR =95% |
| Gibson M et al. [35] |
28 |
Cetuximab +Beva |
2.8m |
RR =27%8.1m
DCR 76% |
| Savvides P et al. [36] |
23 |
TXT +RT+Beva |
78% |
89% DCR 74% |
| Pfister D et al. [37] |
42 |
CDDP+IMRT+Beva |
83% |
88% DCR100% |
| Cohen EE et al. [26] |
48 |
Erlotinib + Beva |
4.1m |
7.1 RR15% |
| Salama JK et al. [23] |
26 |
Beva +Hydroxyurea +5FU + RT |
59% at 2 yr |
OS= 58%
LRC =67%
RR= 86% |
| +Hydroxyurea +5FU +RT |
89% at 2 yr |
OS= 89%
LRC 100%
RR= 100% |
| Argiris A et al. [28] |
37 |
Pem +Beva |
TTP = 5 m |
median OS= 11.3m
ORR= 30%,
CRR = 5%,
DCR= 86%. |
| Harari P.M. et al. [41] |
10 |
wCDDP+Beva+RT |
NR |
22.4 |
| Lee N.Y. et al. [38] |
44* |
Beva + CDDP+IMRTà 3x(Beva+CDDP+5FU) |
71.7%** |
90.9%** |
| Argiris A. et al. [39] |
46 |
Cetuximab+Beva |
2.8m |
7.6m DCR=73% |
| Yao M et al. [29] |
30 |
TXT+RT+Beva biW |
3y 61.7% |
3y OS=68.2%
LRFS= 84.5%
DMFS = 80.5% |
| Yoo DS et al.[27] |
29 |
Beva-erlotinib àRT+ Beva-erlotinib+ CDDP |
3y 82% |
3y OS 86% 3y LRFS=85% 3y
DMFS= 93% |
| Hainsworth JD et al. [40] |
60 |
Beva-5FU-PTX-CDDP àRT+ Beva-erlotinib+ PTX |
3y 71% |
3y OS 82% |
